WO2003044037A3 - Process for the manufacture of human mononuclear phagocytic leukocytes - Google Patents
Process for the manufacture of human mononuclear phagocytic leukocytes Download PDFInfo
- Publication number
- WO2003044037A3 WO2003044037A3 PCT/IL2002/000930 IL0200930W WO03044037A3 WO 2003044037 A3 WO2003044037 A3 WO 2003044037A3 IL 0200930 W IL0200930 W IL 0200930W WO 03044037 A3 WO03044037 A3 WO 03044037A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- phagocytic leukocytes
- manufacture
- mononuclear phagocytic
- human mononuclear
- human
- Prior art date
Links
- 210000000265 leukocyte Anatomy 0.000 title abstract 4
- 230000000242 pagocytic effect Effects 0.000 title abstract 4
- 238000004519 manufacturing process Methods 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- 230000003376 axonal effect Effects 0.000 abstract 1
- 210000004369 blood Anatomy 0.000 abstract 1
- 239000008280 blood Substances 0.000 abstract 1
- 238000002659 cell therapy Methods 0.000 abstract 1
- 238000005119 centrifugation Methods 0.000 abstract 1
- 210000004207 dermis Anatomy 0.000 abstract 1
- 238000011534 incubation Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 210000001616 monocyte Anatomy 0.000 abstract 1
- 208000010125 myocardial infarction Diseases 0.000 abstract 1
- 230000001737 promoting effect Effects 0.000 abstract 1
- 230000008929 regeneration Effects 0.000 abstract 1
- 238000011069 regeneration method Methods 0.000 abstract 1
- 210000003491 skin Anatomy 0.000 abstract 1
- 238000005406 washing Methods 0.000 abstract 1
- 230000029663 wound healing Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0645—Macrophages, e.g. Kuepfer cells in the liver; Monocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4614—Monocytes; Macrophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
- A61K39/4622—Antigen presenting cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/13—Coculture with; Conditioned medium produced by connective tissue cells; generic mesenchyme cells, e.g. so-called "embryonic fibroblasts"
- C12N2502/1323—Adult fibroblasts
Abstract
Priority Applications (10)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
NZ533033A NZ533033A (en) | 2001-11-21 | 2002-11-21 | Process for the manufacture of human mononuclear phagocytic leukocytes |
EP02788490A EP1456355A4 (en) | 2001-11-21 | 2002-11-21 | Process for the manufacture of human mononuclear phagocytic leukocytes |
IL16209402A IL162094A0 (en) | 2001-11-21 | 2002-11-21 | Process for the manufacture of human mononuclear phagocytic leukocytes |
CA2467046A CA2467046C (en) | 2001-11-21 | 2002-11-21 | Process for the manufacture of human mononuclear phagocytic leukocytes |
US10/496,352 US8377692B2 (en) | 2001-11-21 | 2002-11-21 | Process for the manufacturing of human mononuclear phagocytic leukocytes |
MXPA04004813A MXPA04004813A (en) | 2001-11-21 | 2002-11-21 | Process for the manufacture of human mononuclear phagocytic leukocytes. |
AU2002353465A AU2002353465B2 (en) | 2001-11-21 | 2002-11-21 | Process for the manufacture of human mononuclear phagocytic leukocytes |
KR1020047007695A KR101001119B1 (en) | 2001-11-21 | 2002-11-21 | Process for the manufacture of human mononuclear phagocytic leukocytes |
JP2003545673A JP2005519585A (en) | 2001-11-21 | 2002-11-21 | Method for producing human mononuclear phagocytic leukocytes |
IL162094A IL162094A (en) | 2001-11-21 | 2004-05-20 | Process for the manufacture of a culture of activated human mononuclear phagocytic leukocytes |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US33178001P | 2001-11-21 | 2001-11-21 | |
US60/331,780 | 2001-11-21 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2003044037A2 WO2003044037A2 (en) | 2003-05-30 |
WO2003044037A3 true WO2003044037A3 (en) | 2004-04-08 |
Family
ID=23295342
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IL2002/000930 WO2003044037A2 (en) | 2001-11-21 | 2002-11-21 | Process for the manufacture of human mononuclear phagocytic leukocytes |
Country Status (11)
Country | Link |
---|---|
US (1) | US8377692B2 (en) |
EP (1) | EP1456355A4 (en) |
JP (2) | JP2005519585A (en) |
KR (2) | KR101001119B1 (en) |
CN (1) | CN1615357A (en) |
AU (1) | AU2002353465B2 (en) |
CA (1) | CA2467046C (en) |
IL (2) | IL162094A0 (en) |
MX (1) | MXPA04004813A (en) |
NZ (1) | NZ533033A (en) |
WO (1) | WO2003044037A2 (en) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060210543A1 (en) * | 2005-03-21 | 2006-09-21 | Jonathan Leor | Method of treating infarcted myocardium |
US9220813B2 (en) * | 2005-04-18 | 2015-12-29 | Holy Cross Hospital, Inc. | Cell therapy for limiting overzealous inflammatory reactions in tissue healing |
PL1951864T3 (en) * | 2005-11-07 | 2014-10-31 | Pecora & Co Llc | Compositions and methods of vascular injury repair |
US20110076255A1 (en) | 2005-11-07 | 2011-03-31 | Pecora Andrew L | Compositions and methods for treating progressive myocardial injury due to a vascular insufficiency |
US8637005B2 (en) | 2005-11-07 | 2014-01-28 | Amorcyte, Inc. | Compositions and methods of vascular injury repair |
RU2535966C2 (en) * | 2008-09-12 | 2014-12-20 | Криопрашис Криобиоложия Лтда. | Cell-based therapy of ischemic tissue |
WO2010065601A1 (en) * | 2008-12-03 | 2010-06-10 | Amorcyte, Inc. | Infarct area perfusion-improving compositions and methods of vascular injury repair |
US8574902B2 (en) | 2009-03-05 | 2013-11-05 | Macrocure Ltd. | Activated leukocyte composition and uses for wound healing |
CA2754190A1 (en) * | 2009-03-05 | 2010-09-10 | Macrocure, Ltd. | Activated leukocyte composition |
JP2013537889A (en) | 2010-09-09 | 2013-10-07 | マクロキュア,リミテッド | Activated leukocyte conditioned supernatant and use for wound healing |
KR20140107439A (en) * | 2011-12-14 | 2014-09-04 | 예다 리서치 앤드 디벨럽먼트 캄파니 리미티드 | Human monocyte sub-population for treatment of central nervous system injury |
EP2662085A1 (en) * | 2012-05-11 | 2013-11-13 | Humboldt-Universität zu Berlin | Regulatory Macrophages and Their Uses |
CN102703597B (en) * | 2012-06-20 | 2013-10-30 | 安徽信灵检验医学科技有限公司 | Blood leucocyte separating medium and preparation method and vacuum blood collection tube |
AU2014269935B2 (en) | 2013-05-22 | 2019-01-24 | Yeda Research And Development Co. Ltd | Human monocyte sub-population for treatment of eye diseases and disorders |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5800812A (en) * | 1995-09-15 | 1998-09-01 | Yeda Research And Development Co. Ltd. | Methods of use of mononuclear phagocytes to promote axonal regeneration |
US6043089A (en) * | 1995-03-07 | 2000-03-28 | Menicon Co., Ltd. | Skin culture and process for preparing the same |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4086057A (en) * | 1976-07-28 | 1978-04-25 | William Clinton Everett | Ultrasonic disinfection system |
US5292655A (en) * | 1990-01-29 | 1994-03-08 | Wille Jr John J | Method for the formation of a histologically-complete skin substitute |
US6267955B1 (en) | 1995-09-15 | 2001-07-31 | Yeda Research And Development Co. Ltd. | Mononuclear phagocytes and their use to promote axonal regeneration |
US6060515A (en) * | 1997-01-24 | 2000-05-09 | The Regents Of The University Of California | Treatment of skin conditions by use of PPARα activators |
WO1998037881A1 (en) * | 1997-02-28 | 1998-09-03 | Warner Lambert Company | Method of treating or preventing septic shock by administering a mek inhibitor |
CA2320491A1 (en) | 1998-03-30 | 1999-10-07 | I.D.M. Immuno-Designed Molecules | Stimulated monocyte derived cells, their preparation and uses |
US6893462B2 (en) * | 2000-01-11 | 2005-05-17 | Regeneration Technologies, Inc. | Soft and calcified tissue implants |
US20030109583A1 (en) * | 2001-07-25 | 2003-06-12 | Raju Bore G. | Administration of negamycin or deoxynegamycin for the treatment of bacterial infections |
-
2002
- 2002-11-21 US US10/496,352 patent/US8377692B2/en not_active Expired - Fee Related
- 2002-11-21 CA CA2467046A patent/CA2467046C/en not_active Expired - Fee Related
- 2002-11-21 AU AU2002353465A patent/AU2002353465B2/en not_active Ceased
- 2002-11-21 CN CNA028271440A patent/CN1615357A/en active Pending
- 2002-11-21 NZ NZ533033A patent/NZ533033A/en not_active IP Right Cessation
- 2002-11-21 WO PCT/IL2002/000930 patent/WO2003044037A2/en active Application Filing
- 2002-11-21 IL IL16209402A patent/IL162094A0/en active IP Right Grant
- 2002-11-21 MX MXPA04004813A patent/MXPA04004813A/en active IP Right Grant
- 2002-11-21 KR KR1020047007695A patent/KR101001119B1/en not_active IP Right Cessation
- 2002-11-21 KR KR1020107016499A patent/KR20100087781A/en not_active Application Discontinuation
- 2002-11-21 JP JP2003545673A patent/JP2005519585A/en not_active Withdrawn
- 2002-11-21 EP EP02788490A patent/EP1456355A4/en not_active Ceased
-
2004
- 2004-05-20 IL IL162094A patent/IL162094A/en not_active IP Right Cessation
-
2010
- 2010-01-29 JP JP2010018379A patent/JP5087094B2/en not_active Expired - Fee Related
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6043089A (en) * | 1995-03-07 | 2000-03-28 | Menicon Co., Ltd. | Skin culture and process for preparing the same |
US5800812A (en) * | 1995-09-15 | 1998-09-01 | Yeda Research And Development Co. Ltd. | Methods of use of mononuclear phagocytes to promote axonal regeneration |
Non-Patent Citations (1)
Title |
---|
SEPULVEDA-MERRIIL ET AL.: "Antigen-presenting capacity in normal human dermis is mainly subserved by CD1a+ cells", BRITISH JOURNAL OF DERMATOLOGY, vol. 131, 1994, pages 15 - 22, XP001068867 * |
Also Published As
Publication number | Publication date |
---|---|
MXPA04004813A (en) | 2004-08-11 |
KR20100087781A (en) | 2010-08-05 |
JP2010100653A (en) | 2010-05-06 |
IL162094A0 (en) | 2005-11-20 |
WO2003044037A2 (en) | 2003-05-30 |
JP5087094B2 (en) | 2012-11-28 |
US20050129663A1 (en) | 2005-06-16 |
AU2002353465B2 (en) | 2008-10-16 |
US8377692B2 (en) | 2013-02-19 |
EP1456355A2 (en) | 2004-09-15 |
JP2005519585A (en) | 2005-07-07 |
EP1456355A4 (en) | 2005-05-25 |
CA2467046C (en) | 2011-07-19 |
AU2002353465A1 (en) | 2003-06-10 |
NZ533033A (en) | 2006-01-27 |
KR20040076860A (en) | 2004-09-03 |
IL162094A (en) | 2011-09-27 |
CN1615357A (en) | 2005-05-11 |
KR101001119B1 (en) | 2010-12-14 |
CA2467046A1 (en) | 2003-05-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2003044037A3 (en) | Process for the manufacture of human mononuclear phagocytic leukocytes | |
WO2002061090A3 (en) | Prokaryotically produced antibodies and uses thereof | |
WO2001082958A3 (en) | Methods of producing membrane vesicles | |
EP2280030A3 (en) | Nucleic acids and corresponding proteins useful in the detection and treatment of various cancers | |
WO2002064748A8 (en) | Multipotent adult stem cells, sources thereof, methods of obtaining and maintaining same, methods of differentiation thereof, methods of use thereof and cells derived thereof | |
EP2301954A3 (en) | Nucleic acids and corresponding proteins entitled 282P1G3 useful in treatment and detection of cancer | |
WO2003018751A3 (en) | Apparatus and method for electroporation of biological samples | |
WO2001036589A3 (en) | Human ex vivo immune system | |
WO2003083041A3 (en) | Cripto-specific antibodies | |
DE59915205D1 (en) | Structural protein of AAV, its production and use | |
WO1995013385A3 (en) | Thrombin mutants | |
HK1026702A1 (en) | Frangible compounds for pathogen inactivation | |
ATE257390T1 (en) | USE OF A BPI PROTEIN PRODUCT AS AN ANTITHRBOTIC AGENT | |
WO2001059459A3 (en) | Compositions and methods for screening therapeutic agents | |
WO1995025171A3 (en) | Dna sequences for matrix metalloproteases, their production and use | |
AU6745287A (en) | Dna sequences coding for proteins having the biological activity of husi-type i inhibitors, biotechnological methods for the preparation of said proteins and pharmaceutical compositions containing said proteins | |
WO2004098515A3 (en) | Nucleic acids and corresponding proteins entitled 109p1d4 useful in treatment and detection of cancer | |
RS20100249A (en) | Conjugates and methods for the production thereof and their use for transporting molecules via biological membranes | |
ATE512216T1 (en) | NUCLEIC ACID AND THIS CORRESPONDING PROTEIN, CALLED 184P1E2, SUITABLE FOR THE TREATMENT AND DETECTION OF CANCER | |
EP1211311A3 (en) | Cord blood-derived activated lymphocytes and preparations containing said lymphocytes | |
WO2002014369A3 (en) | Human kininogen d5 domain polypeptides and their use | |
WO2001036462A3 (en) | Protein c derivatives | |
AU2001240820A1 (en) | Proteins, genes and their use for diagnosis and treatment of vascular dementia | |
AU2001289930A1 (en) | Method for the production of human antibodies, antibodies thus obtained and their use in therapy and diagnosis | |
AU4037299A (en) | Genetically-modified fibroblasts and the use thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2002353465 Country of ref document: AU Ref document number: 2467046 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1323/DELNP/2004 Country of ref document: IN Ref document number: 01323/DELNP/2004 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 533033 Country of ref document: NZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003545673 Country of ref document: JP Ref document number: 162094 Country of ref document: IL Ref document number: PA/a/2004/004813 Country of ref document: MX Ref document number: 1020047007695 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002788490 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 20028271440 Country of ref document: CN |
|
WWP | Wipo information: published in national office |
Ref document number: 2002788490 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10496352 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 533033 Country of ref document: NZ |
|
WWG | Wipo information: grant in national office |
Ref document number: 533033 Country of ref document: NZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020107016499 Country of ref document: KR |